Background: Some have advocated discontinuing statins in patients with life-limiting conditions. However, the extent of statin use at the end of life has yet to be described and whether statin prescribing may already be influenced by the presence of a recognizable, life-limiting condition is unknown.
INTRODUCTION S
TATINS, OR HMG co-A reductase inhibitors, are a family of medications used for the prevention of atherosclerotic disease. Multiple studies support their long-term use for the primary prevention of nonfatal myocardial infarction in people with cardiovascular risk factors (specifically peripheral artery disease, [1] [2] [3] diabetes, 1, [4] [5] [6] [7] [8] and hyperlipidemia 3, [9] [10] [11] [12] [13] [14] . In addition, statins reduce the likelihood of recurrent myocardial infarction in patients with known coronary artery disease. 3, 7, 8 Statins also reduce the rate of stroke in patients with known cerebrovascular disease. 15 For patients who live the 3-6 years it takes for risk reduction to occur, [15] [16] [17] the benefits of statin therapy clearly outweigh the cost and side effects. For individuals suffering from life-limiting conditions, however, the benefit is likely to be less, and less certain, and the burden may be greater. Although such patients are typically excluded from clinical trials, we know that patients with life-limiting conditions do carry a greater risk of side effects from statin use; myopathy is more likely when patients are older, female, or have low albumins, hypothyroidism, electrolyte disturbances, in-fection, hypoxia, renal insufficiency, hepatic insufficiency, or polypharmacy [18] [19] [20] -conditions frequently present in patients with life-limiting conditions.
Given that the potential burdens of statin therapy for patients nearing the end of life may be great while the benefits are unproven and suspected to be small, Vollrath et al. 21 in the Journal of Palliative Medicine proposed discontinuing statins for patients with lifelimiting conditions. Continuing statins in such patients, they argued, exposes them to risks not worth taking. Additionally, it burdens the health care system with unnecessary costs.
How often and how long patients with recognizable, life-limiting conditions are prescribed statins remains unknown. If the prevalence is low and the time on statins is short, it would suggest that physicians and patients already recognize diseases for which the usefulness of statins is limited. If the prevalence is high and the time on statins is long, however, such findings highlight an opportunity for better, quality care at less cost. For these reasons, we chose to examine the extent and timing of statin use, comparing individuals with recognizable, life limiting conditions to similar individuals who died during the same time period from less recognized causes of limited life expectancy.
We hypothesized that individuals with conditions most clinicians would recognize as incurable, progressive, and life-or "recognizable, life-limiting conditions"-would have statins discontinued sooner than those without. We examined the influence of certain diagnoses rather than patients' prognoses because physicians are more accurate at diagnosing than they are at prognosticating, and because they consider the benefits of treatment more than they consider the patient's prognosis in decisions about withholding or withdrawing care. [22] [23] [24] [25] [26] [27] We expected that statin discontinuation would be less common for patients with known heart disease since, for them, the evidence for continued statin therapy might be stronger. We considered the possibility that comorbidities, severity of illness, as well as number of pills dispensed could affect this relationship. As a secondary objective, we examined the expenditures of the Veterans Health Administration (VHA) on statins for these patients as well.
METHODS

Design
We used a matched case-control design, with cases and controls matched on number of comorbidities, age, and socioeconomic status. Our study was nested within a cohort of patients seen for any service (inpatient, outpatient, laboratory, and/or pharmacy) who died between July 1, 2004 and June 30, 2005 and had statins in hand 6 months prior to death. We chose 6 months as the cutoff point to match the typical life expectancy cut off used to define an illness as "terminal." We chose to examine decedents only (as both cases and controls) to minimize confounding by factors that we could otherwise not adjust for (e.g., social support, function, symptom burden, caregiver status, intensity of care).
Setting
Our population received care at VHA medical centers within Veterans Integrated Service Network (VISN) 11. VISN 11 is one of 22 integrated networks of care for the VHA. VISN 11 represents 8 hospitals, 22 outpatient clinics, and 7 counseling centers in Michigan, Illinois, and Indiana. Together, VISN 11 facilities served approximately 219,978 patients during our period of study. We chose VISN 11 for convenience of data extraction.
Data sources
We used clinical and pharmaceutical data from the VHA. The VHA, which operates on a fixed annual budget that covers pharmaceuticals in addition to staff salaries, clinical services, facilities management, and supplies, closely tracks pharmaceutical expenditures. To prevent the double-digit annual increases in pharmacy costs seen nationally, 28 the VHA has implemented several mechanisms to control pharmacy costs, including a national formulary consisting of over 1200 prescription and over-the-counter drugs in 254 classes. In addition, the VHA maintains a database (Decision Support System Pharmacy National Extracts) to track prescription practices and expenditures, on which we relied for this study. The same source of data has been successfully used to estimate drug costs for the VHA which, in turn, have been extrapolated to the private sector. 29 Clinical data came from national claims data kept at the VHA Austin Automation Center. Figure 1 illustrates the process of case and control selection. Our initial cohort consisted of veterans who died during our period of study and had a statin dispensed prior to death. From this cohort, we selected potential cases as those carrying a recognizable, life-limiting condition prior to death; that is, a condition that most clin-icians would identify as incurable, progressive, and lifeshortening. We identified cases by the presence of a diagnostic claim for a recognizable, life-limiting condition on any single outpatient or inpatient visit to VISN 11 (the former reported by the physician, the latter determined by a coder reviewing the discharge summary). For "recognizable, life-limiting conditions" we used those used to determine the VHA's Palliative Care Index (PCI; Table 1 ). The PCI was developed in 1998 by a group of VHA clinical experts as a performance measure. 30 Within our cohort, we identified 337 cases who carried a PCI diagnosis prior to death.
Case-control selection
We identified controls by matching those remaining in the cohort to cases using propensity scores 31 for independent variables that could confound the relationship between recognizable, life limiting condition and statin discontinuation: namely, number of comorbidities, age, and prescription copay status. Comorbidities were classified according to Quan's modified Charlson Comorbidity Index. 32 We used the count of Charlson comorbidities, rather than the weighted Charlson score 33 as a reflection of burden of illness (or the overall number of conditions a subject carried). Age was the age at death. VHA copay status was included because ability to pay for medications has been shown to be a major driving force behind patient decisions to fill prescriptions and discontinue medications. [34] [35] [36] Copay status at the VHA is determined using the veteran's self-reported net worth, conditions acquired during their time of service (known as "service connection"), and prisoner of war status. There are three categories of copay status: full copay for all medications, full copay for some medications, and no copay on any medications. By matching propensity scores, we identified 1247 patients as controls.
We deliberately chose not to match subjects by ethnicity, gender, and low density lipoprotein (LDL) level. We excluded ethnicity due to the lack of reporting in the VHA Medical Dataset. We excluded
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FIG. 1.
Flow chart for case selection and matching. gender because women in the VHA are few in number (6% of outpatients and 4% of inpatients during the year of the study) 37 and women are usually younger than males (mean age ϭ 48.8 years old for female VHA patients versus 63.6 years old for male VHA patients). We excluded LDL because results were not available for more than two thirds of subjects (less than one fourth of the cases had their LDL levels checked within 6 months before death) and because we felt that LDL status was unlikely to confound the relationship between life-limiting condition and statin discontinuation since LDL level, while a condition for initiation of statin therapy, is not a criterion for discontinuation.
With this sample size, we had 90% power to detect a difference in proportions as small as 10% between the groups (␣ ϭ 0.05).
Outcome of interest
Our outcome of interest was the number of days from the day prescribed statins ran out and the day the patient died. This outcome was determined using the date when a statin was dispensed, how many pills were dispensed at the time, and the date of death. We counted all pills dispensed to patients, even if the prescription had been discontinued at some point after the last refill, in order to account for the true expenditures of the VHA and because we did not have the ability to examine the actual number of pills taken by patients. We did not examine the use of nonstatin lipid-lowering medications since they have not been the focus of debate.
Predictors and confounders
Our main predictor of interest was the presence or absence of a recognizable, life-limiting condition. We chose this predictor in keeping with the mechanism of action that would support our hypothesis; namely, that if a physician discontinues a statin for a patient before death, it is probably because the physician recognizes the patient has an incurable, progressive, and life-limiting illness for whom statins are no longer of value. We chose to measure the presence of a recognizable, life limiting condition using Palliative Care Index (PCI) diagnoses because the diagnoses used to calculate the PCI were chosen to identify patients who most clinicians would agree need palliative care, not only because of their limited life expectancy, but also because of their great burden of suffering and poor quality of life. 30 Patients carrying a PCI diagnoses are those for-whom a discussion of prognosis and goals of care is especially indicated; indeed, the VHA expects 95% of such patients to have documentation of an advance care plan (unless they are receiving hospice or homebased care). A PCI diagnosis, therefore, is one which should flag a physician to discuss, among many things, the goals of continued medical treatment.
Our confounders of interest were weighted Charlson score (as opposed to the Charlson count used for matching) and number of pills supplied (either 30 or 90 for most subjects due to automation at the VHA). We used the weighted Charlson score 32, 33 to reflect the overall severity of illness as modified by age. Some diagnoses were considered in both the calculation of the weighted Charlson score and the determination of the PCI. Despite this, we did not identify any colinearity between the weighted Charlson score and the PCI.
Analyses
We generated frequency statistics to support the matching process as well as describe the study sample. According to the nature of the variables, we compared cases and controls using chi-square, Pearson Product Moment Correlation, Point-Biserial correlation, or Spearman's .
We used survival analysis to test the relationship between days without statins and the presence or absence of a life limiting condition, while controlling for pills supplied and weighted Charlson score.
All statistics were run using SAS ® 9.1.3 software (SAS Institute Inc., Cary, NC).
Human subjects considerations
The study was granted exemption status by the Institutional Review Board at the VA Ann Arbor Healthcare System given the use of deidentified, decedent data.
RESULTS
Study population
Of the 3031 individuals who died in VISN 11 between July 1, 2004 and June 30, 2005, 1584 (52.3%) were receiving statins in the 6 months prior to death. Of those, 337 were diagnosed with a life limiting condition and served as our cases. Using the method described above, we identified 1247 controls.
Cases and controls were mostly elderly, married, white, and male (Table 2) . They did not differ significantly from each other in copay status, gender, race, or age at death. They did differ, however, in marital status (Cramer's V ϭ 0.1086, p ϭ 0.0047) and several important clinical variables determined by their case/control classification.
Cases carried a greater severity of illness than controls did. On average, cases had a weighted Charlson score of 5.6 (standard deviation SD ϭ 3.0) whereas controls had a weighted Charlson score of 2.3 (SD ϭ 2.0). Cases were significantly more likely than controls to suffer from any malignancy ( p Ͻ 0.0001), metastatic cancer (p Ͻ 0.0001), and mild ( p ϭ 0.0008) or moderate to severe ( p Ͻ 0.0001) liver disease; while controls were significantly more likely than cases to suffer from myocardial infarction ( p Ͻ 0.0001), congestive heart failure ( p Ͻ 0.0001), peripheral vascular disease (p ϭ 0.0003), cerebrovascular disease ( p ϭ 0.0296), chronic obstructive pulmonary disease (p Ͻ 0.0001), renal disease ( p Ͻ 0.0103), and diabetes with complications ( p Ͻ 0.0001). Among cases, the most common life limiting conditions (i.e., PCI diagnoses) were advanced cancer (57.9%), COPD (33.8%), and CHF (30.9%).
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To confirm the validity of the PCI as a way of identifying a recognizable life limiting condition, we obtained cause of death data from the National Death Index for cases and controls in aggregate (we did not have access to cause of death by individual). Cases were more likely than controls to die from cancer (odds ratio [OR] 5.49, Յ0.0001) and less likely than controls to die from heart disease (heart attacks and congestive heart failure could not be disentangled) (OR 0.41, Յ0.0001), cerebrovascular disease (acute stroke versus chronic cerebrovascular disease could not be disentangled), and "sudden death" (which included accidents, infections, sepsis, suicide, and assault) (OR 0.31, p ϭ 0.0009). Cases and controls did not differ significantly in other causes of death (specifically, respiratory disease, diabetes, Alzheimer's disease, liver disease, renal disease, hypertension, Parkinson's disease, and "all other").
Statin use
All subjects were receiving statins from the VHA during 6 months prior to death. By the time of death, 51% of cases and 64% of controls were still receiving statins. However, there was no significant difference in the days without statins between cases and controls. Those subjects taken off statins had statins discontinued a mean of 65 days (SD ϭ 49.6) prior to death for cases and 64 days (SD ϭ 50.4) prior to death for controls. Our results did not change after stratifying our analyses by illness subgroup (i.e., cancer, CHF, and COPD).
Most statins were dispensed in 90-day increments, regardless of case control status and the number of pills dispensed did not change over time.
Associations
Days off statins did not associate with having a recognizable, life limiting condition when controlling for weighted Charlson score using Cox proportional hazards modeling (Table 3) . It did, however, associate marginally with the number of days of pills supplied (hazard ratio [HR] ϭ 1.005, p ϭ 0.0370) , such that for every additional 1 day of pills supplied there was a 0.5% increased risk of not being taken off a statin. VISN 11 spent $19, 655 .83 for statins dispensed to 335 patients within 6 months of their death from a known life-limiting condition (2 cases were missing from the pharmaceutical database).
Cost of statin therapy
DISCUSSION
A large proportion of patients (52.3%) receive statins during their last year of life at the VHA. The diagnosis of a recognizable, life limiting illness does not change the timing of or likelihood that a statin will be discontinued prior to death, even for patients without cardiovascular disease. These findings suggest that physicians may not recognize certain conditions as progressive and life limiting, or reassess the benefits and burdens of continued statin therapy when they do. Alternatively, it could mean that physicians find discontinuation of preventive therapies like statins difficult to discuss or that patients are not receptive to the notion that preventive therapies are no longer warranted.
While we saw no difference in statin prescribing patterns by presence of recognizable, life limiting condition, we did witness some statin discontinuation for all patients over time. We feel this decline likely reflects the nature of medications which have side effects, as well as issues with noncompliance, intolerance, and bureaucratic errors. Unfortunately, our data did not include reasons for discontinuation to allow us to test this hypothesis.
Some might argue that our findings can be explained by excess similarity, or colinearity, between our case and control groups. Indeed, our subject selection and case matching protocols were designed to make the two groups as comparable as possible with one exception-the presence of a recognizable, life-limiting condition for cases as defined by the VHA's PCI. That single difference allowed us to test the hypothesis that SILVEIRA ET AL. 690 individuals who die of conditions recognized to limit life expectancy and burden have statins discontinued sooner than similar individuals who die of causes that are not as predictably fatal or recognized. Some might not agree with our use of PCI diagnoses as "flags" for a recognizable, life limiting condition-however, because it is commonly used to measure palliative care workload within the VHA, we felt it had "face validity" and was appropriate. Still, the PCI has never been empirically validated as a prognosticator of death and some may consider this a major limitation of this work. We wish to emphasize, however, that our predictor of interest was not life expectancy per se, but the "presence of a recognizable, life-limiting condition." Out of many measures we considered, we chose the PCI for our predictor of interest because the PCI most represented those conditions that commonly trigger a discussion of goals of care and the purpose of continued medical treatment.
Others may question the generalizability of our findings. This is a common concern when studies are conducted using VHA data. Admittedly, our subjects are not typical of the general population and our system is not representative of most medical care. However, for us, the feasibility of this study was a strong concern and the convenience of VHA data cannot be overstated. We do acknowledge that in a different population of patients, especially in one that pays out of pocket for medications, our findings may not stand.
Limitations aside, we believe these results highlight an opportunity to reduce the burden of medical therapy upon severely ill patients who often take many medications, have difficulty swallowing, are at greater risk for side effects, and must provide co-pays. Discontinuing statins for such patients not only reduces their burden, but also makes their therapy consistent with the goals of care, especially when cure is no longer a possibility. Doing otherwise could send them mixed messages, making it even more difficult to overcome denial, accept fate, and participate in advance care planning.
In addition to benefiting patients, discontinuing statins may benefit the health care system as a whole by stemming pharmaceutical costs. During our study period, VISN 11 spent $9.78 per month per patient, or $19,655 total, on statin therapy for 335 patients during their last 6 months of life. While this is a substantial amount for the VHA, it is a fraction of what would have been spent in the private sector where a month's supply of statin costs between $63.59 and $110.99. 21 Using these numbers, we estimate that in the private sector, $127,816 to $223,090 dollars would have been spent on the same 335 decedents.
Discontinuing statins in such patients, therefore, could save a lot of money. This cost savings is especially relevant to hospice, which operates on a fixed per diem and must provide all medicationssome hospices do provide nonpalliative medications such as statins (in 2004, Silveira 38 found that 24% of hospices in Michigan are willing to provide medications not directly related to the terminal diagnosis).
This study is meant to describe the current pattern of statin use at the end of life in the VHA, not recommend the appropriate timing or criteria for statin discontinuation. When and where to discontinue statins are questions we pose to the community of palliative care and hospice providers at large. For the time being, without better data on the benefits and burdens of statin therapy for patients with progressive, life limiting conditions, we must be guided by clinical prudence.
In conclusion, we find that statins are prescribed frequently in the last year of life for patients carrying recognizable, life-limiting conditions and that the patient's diagnosis does not appear to affect prescribing patterns. The small amount of discontinuation we did observe in the last 6 months of life occurs for reasons we have yet to understand. Still, our findings highlight an area for discussion as a specialty and potential intervention in the future.
